Sherer Todd B, Fiske Brian K, Svendsen Clive N, Lang Anthony E, Langston J William
Michael J. Fox Foundation for Parkinson's Research, New York, New York 10005, USA.
Mov Disord. 2006 Feb;21(2):136-41. doi: 10.1002/mds.20861.
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial-derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined.
开发一种针对帕金森病（PD）的神经保护或神经再生疗法将是一项重大的治疗进展。不幸的是，最近一项将神经营养因子——胶质细胞源性神经营养因子（GDNF）直接注入大脑的对照临床研究结果并未证明这种治疗的有效性和安全性。对现有数据的批判性回顾表明，在确定GDNF作为PD治疗方法的未来之前，还有一些问题需要解答。
